Key result
Sacubitril/valsartan reduces mortality ~16% vs enalapril in patients with HFrEF.
Why the study?
Does sacubitril/valsartan improve clinical outcomes and cardiac remodeling in patients with low ejection fraction heart failure?
Does sacubitril/valsartan improve clinical outcomes and cardiac remodeling in patients with low ejection fraction heart failure?
Sacubitril/valsartan provides comprehensive benefits in HFrEF, including reduced mortality, decreased hospitalizations, and improved cardiac remodeling and quality of life.
Answers are grounded in this paper and cite their sources.
Supports sacubitril/valsartan in HFrEF; leaves open prospective confirmation of remodeling benefits.
Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.
No takes yet. Share an insight, caveat, or question.
Aşkın et al. (2022) conducted a review in Low Ejection Fraction Heart Failure. Sacubitril/Valsartan vs. Enalapril was evaluated on Mortality (RR 0.84, 95% CI 0.76-0.93, p=0.009). Sacubitril/valsartan reduced the risk of mortality by 16% (RR 0.84) compared to enalapril in patients with low ejection fraction heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: